FDA Backs Oryzon’s Phase III Plans For Borderline Personality Disorder Drug

Would-be partners for the Spanish firm’s vafidemstat will be closely following the news that regulators in the US are looking favorably on the LSD1 inhibitor’s potential as a therapy for the debilitating psychiatric illness.